Evidence map›Paper›PMID 34980595›Full record

ArticleMolecular cancer research : MCR2022

GFI1 Cooperates with IKZF1/IKAROS to Activate Gene Expression in T-cell Acute Lymphoblastic Leukemia.

Wenxiang Sun, Jingtao Guo, David McClellan, Alexandra Poeschla, Diana Bareyan, Mattie J Casey, Bradley R Cairns, Dean Tantin, Michael E Engel

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Wenxiang SunDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah.
Jingtao GuoHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
David McClellanHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-4470-2437
Alexandra PoeschlaDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah.
Diana BareyanHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Mattie J CaseyHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Bradley R CairnsHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-9864-8811
Dean TantinDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah.
Michael E EngelHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-2878-9707
University of Utah · USHoward Hughes Medical Institute · USHuntsman Cancer Institute · USPrimary Children's Hospital · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Role of Transcription Coactivator OCA-B in Gene Poising and Immunological MemoryR01AI100873 · NIAID · UNIVERSITY OF UTAH · PI TANTIN, DEAN · 2013 to 2022
$3.8M
Targeting the GFI1-LSD1 Axis in T-Cell Acute Lymphoblastic LeukemiaR01CA201235 · NCI · UNIVERSITY OF VIRGINIA · PI ENGEL, MICHAEL E · 2017 to 2022
$1.9M
Developmental gene poising by Oct transcription factorsR01GM122778 · NIGMS · UNIVERSITY OF UTAH · PI TANTIN, DEAN · 2018 to 2021
$1.2M
NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA201235NIAID NIH HHS R01 AI100873NIGMS NIH HHS R01 GM122778
6 · The paper itself

Abstract

Growth factor independence-1 (GFI1) is a transcriptional repressor and master regulator of normal and malignant hematopoiesis. Repression by GFI1 is attributable to recruitment of LSD1-containing protein complexes via its SNAG domain. However, the full complement of GFI1 partners in transcriptional control is not known. We show that in T-acute lymphoblastic leukemia (ALL) cells, GFI1 and IKAROS are transcriptional partners that co-occupy regulatory regions of hallmark T-cell development genes. Transcriptional profiling reveals a subset of genes directly transactivated through the GFI1-IKAROS partnership. Among these is NOTCH3, a key factor in T-ALL pathogenesis. Surprisingly, NOTCH3 expression by GFI1 and IKAROS requires the GFI1 SNAG domain but occurs independent of SNAG-LSD1 binding. GFI1 variants deficient in LSD1 binding fail to activate NOTCH3, but conversely, small molecules that disrupt the SNAG-LSD1 interaction while leaving the SNAG primary structure intact stimulate NOTCH3 expression. These results identify a noncanonical transcriptional control mechanism in T-ALL which supports GFI1-mediated transactivation in partnership with IKAROS and suggest competition between LSD1-containing repressive complexes and others favoring transactivation. IMPLICATIONS: Combinatorial diversity and cooperation between DNA binding proteins and complexes assembled by them can direct context-dependent transcriptional outputs to control cell fate and may offer new insights for therapeutic targeting in cancer.

Indexed as

DNA-Binding ProteinsGene Expression Regulation, LeukemicIkaros Transcription FactorPrecursor T-Cell Lymphoblastic Leukemia-LymphomaTranscription FactorsHumansDNA-Binding ProteinsGFI1 protein, humanIkaros Transcription FactorIKZF1 protein, humanTranscription Factors

Identifiers

PMID34980595
PMCPMC8983472
OpenAlexW4205203006

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.